Gryphon Financial Partners LLC raised its stake in Celgene Co. (NASDAQ:CELG) by 793.9% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,923 shares of the biopharmaceutical company’s stock after buying an additional 2,596 shares during the quarter. Gryphon Financial Partners LLC’s holdings in Celgene were worth $262,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently added to or reduced their stakes in the company. Johnson Financial Group Inc. raised its position in shares of Celgene by 4.5% during the second quarter. Johnson Financial Group Inc. now owns 13,100 shares of the biopharmaceutical company’s stock worth $1,040,000 after purchasing an additional 567 shares during the period. Wetherby Asset Management Inc. raised its position in shares of Celgene by 5.4% during the second quarter. Wetherby Asset Management Inc. now owns 11,857 shares of the biopharmaceutical company’s stock worth $942,000 after purchasing an additional 603 shares during the period. Tompkins Financial Corp raised its position in shares of Celgene by 3.8% during the second quarter. Tompkins Financial Corp now owns 18,059 shares of the biopharmaceutical company’s stock worth $1,434,000 after purchasing an additional 656 shares during the period. Hills Bank & Trust Co. raised its position in shares of Celgene by 4.9% during the third quarter. Hills Bank & Trust Co. now owns 14,255 shares of the biopharmaceutical company’s stock worth $1,276,000 after purchasing an additional 672 shares during the period. Finally, Coastline Trust Co raised its position in shares of Celgene by 14.5% during the second quarter. Coastline Trust Co now owns 5,370 shares of the biopharmaceutical company’s stock worth $427,000 after purchasing an additional 680 shares during the period. 73.58% of the stock is currently owned by hedge funds and other institutional investors.

CELG stock opened at $74.02 on Friday. The company has a quick ratio of 1.99, a current ratio of 2.13 and a debt-to-equity ratio of 4.06. The company has a market capitalization of $52.77 billion, a price-to-earnings ratio of 10.82, a P/E/G ratio of 0.47 and a beta of 1.53. Celgene Co. has a twelve month low of $70.09 and a twelve month high of $110.81.

Celgene (NASDAQ:CELG) last posted its quarterly earnings results on Thursday, October 25th. The biopharmaceutical company reported $2.29 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.02 by $0.27. The firm had revenue of $3.89 billion during the quarter, compared to the consensus estimate of $3.83 billion. Celgene had a return on equity of 108.76% and a net margin of 19.64%. On average, research analysts predict that Celgene Co. will post 7.45 earnings per share for the current fiscal year.

A number of equities research analysts have recently commented on CELG shares. BidaskClub raised Celgene from a “hold” rating to a “buy” rating in a research report on Thursday, August 16th. Mizuho reiterated a “buy” rating and set a $129.00 price objective on shares of Celgene in a report on Tuesday, July 31st. JPMorgan Chase & Co. reiterated a “buy” rating on shares of Celgene in a report on Thursday, October 25th. UBS Group set a $94.00 price objective on Celgene and gave the stock a “buy” rating in a report on Saturday, October 27th. Finally, Morgan Stanley increased their price objective on Celgene from $90.00 to $91.00 and gave the stock an “equal weight” rating in a report on Friday, July 13th. Three research analysts have rated the stock with a sell rating, eleven have issued a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $117.91.

TRADEMARK VIOLATION WARNING: “Gryphon Financial Partners LLC Has $262,000 Holdings in Celgene Co. (CELG)” was published by Daily Political and is the property of of Daily Political. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this piece of content can be read at https://www.dailypolitical.com/2018/11/10/gryphon-financial-partners-llc-has-262000-holdings-in-celgene-co-celg.html.

Celgene Profile

Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers.

Recommended Story: Trading Strategy Methods and Types

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.